Skip to main content
LLM 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Wendy Béguelin, PhD

Weill Cornell Medicine
New York, New York, United States

Dr. Wendy Béguelin is an Assistant Professor at Weill Cornell working in the field of lymphoma
epigenetics and experimental therapeutics. She obtained her PhD at the University of Buenos Aires, Argentina.
As undergraduate and graduate student at the University of Buenos Aires she received extensive training in the
investigation of cell biology and signal transduction with studies on epigenetic gene regulation and transcription
factor binding. As a postdoctoral scientist at Weill Cornell Medical College, under the supervision and mentorship
of Prof. Ari Melnick, she has identified novel and druggable epigenetic and transcriptional mechanisms in B-cell
differentiation and lymphomagenesis, which played a critical role in the FDA approval of the first EZH2 inhibitor
Tazemetostat. She is currently an R01-funded Assistant Professor at Weill Cornell Medicine. Dr. Béguelin
characterized the role of EZH2 in humoral immunity and lymphomagenesis, and the mechanisms through which
EZH2 mutations –occurring in human lymphoma patients– reprogram the epigenome to mediate malignant
transformation. Dr. Béguelin has also mentored, supervised and trained a number of medical fellows, postdocs,
graduate and undergraduate students. She developed a network of close collaborators at national and
international institutions, including clinical investigators and pharma companies linked to the EZH2 clinical trials.
Dr. Béguelin is committed to a career in lymphoma research, bringing new ideas into the field of epigenetic
control of lymphomagenesis and making discoveries that can be translated into diagnostic and therapeutic
modalities to improve patient outcomes.

Presentation(s):